Activity of Aztreonam-Avibactam and Comparators against Difficult-to- Treat Resistant (DTR) Enterobacterales from Patients with Pneumonia or Intra-abdominal Infections (IAI) in European Medical Centers (2020-2024)
Activity of Aztreonam-Avibactam and Comparators against Difficult-to- Treat Resistant (DTR) Enterobacterales from Patients with Pneumonia or Intra-abdominal Infections (IAI) in European Medical Centers (2020-2024). Lead author: Helio S. Sader, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #1273
Activity of manogepix against Candida auris
Activity of manogepix against Candida auris. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3308
Activity of Zosurabalpin Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) Isolates Producing NDM and/or Oxacillinase Enzymes
Activity of Zosurabalpin Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) Isolates Producing NDM and/or Oxacillinase Enzymes. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #1351
Activity of manogepix against invasive fungal infections from immunocompromised hosts
Activity of manogepix against invasive fungal infections from immunocompromised hosts. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3309
Activity of mold-active azole agents against Aspergillus fumigatus clinical isolates nonwildtype to azoles and isolates displaying CYP51 alterations
Activity of mold-active azole agents against Aspergillus fumigatus clinical isolates nonwildtype to azoles and isolates displaying CYP51 alterations. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3323
Activity of Manogepix and Comparator Antifungals Against Mould Isolates Collected from Invasive Infections in Intensive Care Units (ICU) and Non-ICU Settings (2017–2024)
Activity of Manogepix and Comparator Antifungals Against Mould Isolates Collected from Invasive Infections in Intensive Care Units (ICU) and Non-ICU Settings (2017–2024). Lead author: Michael Huband, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3320
Characterization of Candida auris (Candidozyma auris) from a worldwide surveillance program over 12 years
Characterization of Candida auris (Candidozyma auris) from a worldwide surveillance program over 12 years. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3305
Occurrences by Region and Age Groups and Antifungal Susceptibility Profiles of Opportunistic Filamentous Fungal Pathogens Collected in 8 Years of Global Surveillance
Occurrences by Region and Age Groups and Antifungal Susceptibility Profiles of Opportunistic Filamentous Fungal Pathogens Collected in 8 Years of Global Surveillance. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3323
Activity of Manogepix and Comparator Antifungal Agents Against Yeast Isolates Collected from Invasive Infections in Intensive Care Unit (ICU) and Non-ICU Settings
Activity of Manogepix and Comparator Antifungal Agents Against Yeast Isolates Collected from Invasive Infections in Intensive Care Unit (ICU) and Non-ICU Settings. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3310
Isavuconazole activity against moulds in ICU and non-ICU infections
Isavuconazole activity against moulds in ICU and non-ICU infections. Lead author: SJ Ryan Arends, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3303
Comparison of manogepix activity against 2,659 community-acquired and nosocomial mould isolates from the SENTRY Antimicrobial Surveillance Program (2017–2024)
Comparison of manogepix activity against 2,659 community-acquired and nosocomial mould isolates from the SENTRY Antimicrobial Surveillance Program (2017–2024). Lead author: Michael Huband, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3309
Lefamulin Activity against Bacterial Pathogens Typically Causing Community-Acquired Pneumonia Collected from European Medical Centres in 2023 and 2024
Lefamulin Activity against Bacterial Pathogens Typically Causing Community-Acquired Pneumonia Collected from European Medical Centres in 2023 and 2024. Lead author: Helio S. Sader, presented at ESCMID Global 2026, April 20, Munich, Germany
P #1245
Activity of rezafungin against Aspergillus spp.
Activity of rezafungin against Aspergillus spp. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3304
Isavuconazole activity against moulds in nosocomial and community-acquired infections
Isavuconazole activity against moulds in nosocomial and community-acquired infections. Lead author: SJ Ryan Arends, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3312
Activity of tebipenem against Enterobacterales, including molecularly characterized isolates causing urinary tract and bloodstream infections in the United States and United Kingdom in 2023-2024
Activity of tebipenem against Enterobacterales, including molecularly characterized isolates causing urinary tract and bloodstream infections in the United States and United Kingdom in 2023-2024. Lead author: Timothy Doyle, presented at ESCMID Global 2026, April 19, Munich, Germany
Poster #2644
In vitro Activity of Zosurabalpin and Comparator Agents Tested Against Acinetobacter baumannii-calcoaceticus Complex Isolates From China
In vitro Activity of Zosurabalpin and Comparator Agents Tested Against Acinetobacter baumannii-calcoaceticus Complex Isolates From China. Lead author: Joshua M. Maher, presented at APCCMI 2025, Nov 3, Bangkok, Thailand
Poster #RES-162
Activity of Zosurabalpin and Comparator Antimicrobial Agents Tested Against Acinetobacter baumannii-calcoaceticus Complex (ABC) Isolates Collected Worldwide in 2024
Activity of Zosurabalpin and Comparator Antimicrobial Agents Tested Against Acinetobacter baumannii-calcoaceticus Complex (ABC) Isolates Collected Worldwide in 2024. Lead author: Joshua M. Maher, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1333
Activity of manogepix against surveillance yeast isolates collected from the United States in 2023
Activity of manogepix against surveillance yeast isolates collected from the United States in 2023. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1195
In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024
In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024. Lead authors: R Kapoor, TB Doyle, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1214
Geographic distribution, MIC testing, and susceptibility rates of Candida auris isolates collected in the United States since 2014
Geographic distribution, MIC testing, and susceptibility rates of Candida auris isolates collected in the United States since 2014. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1196
A 10-year Trend on Antimicrobial Resistance of Pseudomonas aeruginosa from United States Medical Centers: Results from the INFORM Surveillance Program (2015–2024)
A 10-year Trend on Antimicrobial Resistance of Pseudomonas aeruginosa from United States Medical Centers: Results from the INFORM Surveillance Program (2015–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1313
Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024
Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024. Lead author: Mariana Castanheira, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1279
In Vitro Activity of Cefiderocol against Resistant Subsets of Pseudomonas aeruginosa Collected from United States Hospitals during 2020–2024
In Vitro Activity of Cefiderocol against Resistant Subsets of Pseudomonas aeruginosa Collected from United States Hospitals during 2020–2024. Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1287
Activity of Aztreonam-Avibactam and Comparators against Difficult-to-Treat Resistant (DTR) Enterobacterales from United States Medical Centers (2020–2024)
Activity of Aztreonam-Avibactam and Comparators against Difficult-to-Treat Resistant (DTR) Enterobacterales from United States Medical Centers (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1316
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized ESBL- and carbapenemase-positive subsets causing urinary tract infections in United States Medical Centers (2023)
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized ESBL- and carbapenemase-positive subsets causing urinary tract infections in United States Medical Centers (2023). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1203
Antimicrobial Activity of Aztreonam-Avibactam and Molecular Characterization of Enterobacterales Resistant to Ceftazidime-Avibactam and/or Meropenem-Vaborbactam from United States Medical Centers (2016–2024)
Antimicrobial Activity of Aztreonam-Avibactam and Molecular Characterization of Enterobacterales Resistant to Ceftazidime-Avibactam and/or Meropenem-Vaborbactam from United States Medical Centers (2016–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1319
Performance of the VITEK 2 with Advance Expert System as a Fast Method for Determination of Antimicrobial Susceptibility Against 400 Enterobacterales Isolates from North America and Latin America (2022)
Performance of the VITEK 2 with Advance Expert System as a Fast Method for Determination of Antimicrobial Susceptibility Against 400 Enterobacterales Isolates from North America and Latin America (2022). Lead author: Michael D. Huband, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1697
Antimicrobial susceptibility of S. maltophilia and B. cepacia species complex isolated from patients with pneumonia in United States hospitals (2022–2024)
Antimicrobial susceptibility of S. maltophilia and B. cepacia species complex isolated from patients with pneumonia in United States hospitals (2022–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1320
Activity of Delafloxacin and Comparator Agents Against Bacterial Isolates from Patients with Diabetic Foot Infection in the United States and Europe (2017–2023)
Activity of Delafloxacin and Comparator Agents Against Bacterial Isolates from Patients with Diabetic Foot Infection in the United States and Europe (2017–2023). Lead author: Michael D. Huband, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1340
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from Europe, Asia, and Latin America (2020–2024)
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from Europe, Asia, and Latin America (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1314
Activity of isavuconazole against contemporary Mucorales from a worldwide surveillance program
Activity of isavuconazole against contemporary Mucorales from a worldwide surveillance program. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1193
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents Tested against Enterobacterales from European Hospitals Analysed by Infection Type (2022–2024)
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents Tested against Enterobacterales from European Hospitals Analysed by Infection Type (2022–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1317
In vitro activity of gepotidacin and comparator agents against a collection of Escherichia coli and Klebsiella pneumoniae urine isolates from the United States during 2023
In vitro activity of gepotidacin and comparator agents against a collection of Escherichia coli and Klebsiella pneumoniae urine isolates from the United States during 2023. Lead author: S.J. Ryan Arends, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1174
Activity of aztreonam-avibactam tested against genetically characterized non-carbapenemase-producing carbapenem-resistant Enterobacterales
Activity of aztreonam-avibactam tested against genetically characterized non-carbapenemase-producing carbapenem-resistant Enterobacterales. Lead author: Mariana Castanheira, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1332
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in United States Medical Centers (2023)
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in United States Medical Centers (2023). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1204
In vitro Activity of Cefiderocol against Carbapenem-Nonsusceptible Acinetobacter baumannii-calcoaceticus Complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2024)
In vitro Activity of Cefiderocol against Carbapenem-Nonsusceptible Acinetobacter baumannii-calcoaceticus Complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2024). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1286
Activity of Aztreonam-Avibactam and Ceftazidime-Avibactam against Enterobacterales and Pseudomonas aeruginosa Causing Infections in Immunosuppressed Patients from United States Medical Centers (2019–2024)
Activity of Aztreonam-Avibactam and Ceftazidime-Avibactam against Enterobacterales and Pseudomonas aeruginosa Causing Infections in Immunosuppressed Patients from United States Medical Centers (2019–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1315
Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024
Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024. Lead author: Mariana Castanheira, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1278
In vitro activity of EL219 (SF001) and amphotericin B agents against a collection of Candida and Aspergillus isolates collected in 2024
In vitro activity of EL219 (SF001) and amphotericin B agents against a collection of Candida and Aspergillus isolates collected in 2024. Lead author: S.J. Ryan Arends, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1205
Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023
Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023. Lead authors: R Kapoor, TB Doyle, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1213
Activity of manogepix against mould isolates from the US collected in 2023
Activity of manogepix against mould isolates from the US collected in 2023. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1194
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Stenotrophomonas maltophilia Isolates from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia (2020–2024)
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Stenotrophomonas maltophilia Isolates from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1318
Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales isolates causing infections in hospitals in Europe and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales isolates causing infections in hospitals in Europe and adjacent regions (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #E0721
Activity of omadacycline against multidrug-resistant and molecularly characterized Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals (2020–2023)
Activity of omadacycline against multidrug-resistant and molecularly characterized Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1314
Zosurabalpin (5 μg) disk diffusion quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 1 and Tier 2 criteria
Zosurabalpin (5 μg) disk diffusion quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 1 and Tier 2 criteria. Lead author: Michael D. Huband, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #2545
Gepotidacin activity against and analysis of susceptibility to oral standard-of-care antibiotics for urinary tract infections caused by Escherichia coli and Klebsiella pneumoniae collected in Europe in 2023
Gepotidacin activity against and analysis of susceptibility to oral standard-of-care antibiotics for urinary tract infections caused by Escherichia coli and Klebsiella pneumoniae collected in Europe in 2023. Lead author: S. J. Ryan Arends, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1216
Activity of gepotidacin against molecularly characterized β-lactamase-producing E. coli and K. pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2023)
Activity of gepotidacin against molecularly characterized β-lactamase-producing E. coli and K. pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1217
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1351
Increase in blaNDM-1 among carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex clinical isolates collected in 2023 from U.S. and European medical centres
Increase in blaNDM-1 among carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex clinical isolates collected in 2023 from U.S. and European medical centres. Lead author: John H. Kimbrough, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1273
Gepotidacin activity against E. coli and K. pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2023)
Gepotidacin activity against E. coli and K. pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1216
